Phase 2 Clinical Study

Planning underway

Eloxx is advancing a dedicated Phase 2 clinical study of exaluren in patients with autosomal dominant polycystic kidney disease (ADPKD) caused by nonsense mutations in PKD1 or PKD2. No trial is currently enrolling.

We will announce the study and share site information as the program advances. Check back here for further updates.

Patients with a confirmed PKD1 or PKD2 nonsense mutation who are interested in future research opportunities should speak with their nephrologist about genetic testing.